In a report released Friday, the researchers biopharmaceutical company Gilead Sciences said COVID-19 remdesivir patients learn to not get receive treatment of its lower antiviral drug mortality rates and better recovery time than that. The researchers compared 312 people COVID-19 in the hospital and received remdesivir to 818 people with severe cases similarly treated with standard therapy, but they must have mechanical ventilation to breathe. Compared to people in the latter group it showed the ones that get remdesivir a lower risk of mortality of 62% during the study period. In addition, about 75% of patients recovering receptacle remdesivir day 14 after admission, which compared to 59% who did not get the drug. The results were presented at the International AIDS Conference in Virtual COVID-19 conference, co-sponsored by Gilead. The analysis did not follow the strict gold standard of an experimental treatment group with a control group in the same study of comparison, a method that the two similar groups as possible and better accounts potentially confounding factors assured. remdesivir studio earlier that meets these criteria, conducted by the National Institute of Allergy and Infectious Diseases and the end of April reports they have shown that people have had a shorter recovery time under remdesivir. to find, given the urgency of the treatment during a pandemic caused rapid deterioration in deciding the results of the NIH that future studies of the drug (such as combined tests with other drugs, including anti-inflammatory drugs) a placebo group would not need. Gilead Analysis is the best thing for a randomized, placebo-controlled, and the company’s researchers acknowledge that further studies are needed to confirm the reduction in mortality. “To address the urgency of the pandemic continues, we will share data with the research community as soon as possible with the aim of transparent and timely information on new developments remdesivir” Gilead Sciences Chief Medical Officer Merdad Parsey said in a statement. Gilead also reported additional data that remdesivir provided similar benefits for people of ethnic and racial groups, shows that appear and COVID-19 to be more sensitive to its effects. In a further analysis of people taking the drug in the early years of the pandemic (under the name of compassionate use program) received, the researchers found that children and women are pregnant, the drug had similar benefits improvement of oxygen measurements. Remdesivir is not yet approved by the Food and Drug Administration (FDA), but the Agency will issue an Emergency Use Authorization (EUA) for the May 1 doctors the medicine for seriously ill patients. can apply image rights by Ulrich Perrey AFP / Getty Images
The company that makes Remdesivir says that greatly reduces COVID-19 dead
